243 related articles for article (PubMed ID: 8950785)
1. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor VIII complexed with von Willebrand factor.
Suzuki T; Arai M; Amano K; Kagawa K; Fukutake K
Thromb Haemost; 1996 Nov; 76(5):749-54. PubMed ID: 8950785
[TBL] [Abstract][Full Text] [Related]
2. Autoantibody to factor VIII that has less reactivity to factor VIII/von Willebrand factor complex.
Amano K; Arai M; Koshihara K; Suzuki T; Kagawa K; Nishida Y; Fukutake K
Am J Hematol; 1995 Aug; 49(4):310-7. PubMed ID: 7639276
[TBL] [Abstract][Full Text] [Related]
3. Influence of von Willebrand factor on the reactivity of human factor VIII inhibitors with factor VIII.
Gensana M; Altisent C; Aznar JA; Casaña P; Hernández F; Jorquera JI; Magallón M; Massot M; Puig L
Haemophilia; 2001 Jul; 7(4):369-74. PubMed ID: 11442641
[TBL] [Abstract][Full Text] [Related]
4. A role for the C2 domain of factor VIII in binding to von Willebrand factor.
Saenko EL; Shima M; Rajalakshmi KJ; Scandella D
J Biol Chem; 1994 Apr; 269(15):11601-5. PubMed ID: 7512568
[TBL] [Abstract][Full Text] [Related]
5. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine.
Shima M; Scandella D; Yoshioka A; Nakai H; Tanaka I; Kamisue S; Terada S; Fukui H
Thromb Haemost; 1993 Mar; 69(3):240-6. PubMed ID: 7682339
[TBL] [Abstract][Full Text] [Related]
6. Common inhibitory effects of human anti-C2 domain inhibitor alloantibodies on factor VIII binding to von Willebrand factor.
Shima M; Nakai H; Scandella D; Tanaka I; Sawamoto Y; Kamisue S; Morichika S; Murakami T; Yoshioka A
Br J Haematol; 1995 Nov; 91(3):714-21. PubMed ID: 8555081
[TBL] [Abstract][Full Text] [Related]
7. Slowed release of thrombin-cleaved factor VIII from von Willebrand factor by a monoclonal and a human antibody is a novel mechanism for factor VIII inhibition.
Saenko EL; Shima M; Gilbert GE; Scandella D
J Biol Chem; 1996 Nov; 271(44):27424-31. PubMed ID: 8910322
[TBL] [Abstract][Full Text] [Related]
8. Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model.
Batsuli G; Ito J; Mercer R; Baldwin WH; Cox C; Parker ET; Healey JF; Lollar P; Meeks SL
J Thromb Haemost; 2018 Sep; 16(9):1779-1788. PubMed ID: 29981270
[TBL] [Abstract][Full Text] [Related]
9. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.
Scandella D; Gilbert GE; Shima M; Nakai H; Eagleson C; Felch M; Prescott R; Rajalakshmi KJ; Hoyer LW; Saenko E
Blood; 1995 Sep; 86(5):1811-9. PubMed ID: 7544643
[TBL] [Abstract][Full Text] [Related]
10. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate Study Groups.
Prescott R; Nakai H; Saenko EL; Scharrer I; Nilsson IM; Humphries JE; Hurst D; Bray G; Scandella D
Blood; 1997 May; 89(10):3663-71. PubMed ID: 9160671
[TBL] [Abstract][Full Text] [Related]
11. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
[TBL] [Abstract][Full Text] [Related]
12. Epitope specificity of anti-FVIII antibodies during immune tolerance therapy with factor VIII preparation containing von Willebrand factor.
Kallas A; Pooga M; Benhida A; Jacquemin M; Saint-Remy JM
Thromb Res; 2002 Sep; 107(6):291-302. PubMed ID: 12565716
[TBL] [Abstract][Full Text] [Related]
13. The acidic region of the factor VIII light chain and the C2 domain together form the high affinity binding site for von willebrand factor.
Saenko EL; Scandella D
J Biol Chem; 1997 Jul; 272(29):18007-14. PubMed ID: 9218428
[TBL] [Abstract][Full Text] [Related]
14. Different factor VIII neutralizing effects on anti-factor VIII inhibitor antibodies associated with epitope specificity and von Willebrand factor.
Yada K; Nogami K; Shima M
Br J Haematol; 2013 Oct; 163(1):104-11. PubMed ID: 23889549
[TBL] [Abstract][Full Text] [Related]
15. To serve and protect: The modulatory role of von Willebrand factor on factor VIII immunogenicity.
Hartholt RB; van Velzen AS; Peyron I; Ten Brinke A; Fijnvandraat K; Voorberg J
Blood Rev; 2017 Sep; 31(5):339-347. PubMed ID: 28716211
[TBL] [Abstract][Full Text] [Related]
16. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
[TBL] [Abstract][Full Text] [Related]
17. Immunodominant T-cell epitopes in the factor VIII C2 domain are located within an inhibitory antibody binding site.
Pratt KP; Qian J; Ellaban E; Okita DK; Diethelm-Okita BM; Conti-Fine B; Scott DW
Thromb Haemost; 2004 Sep; 92(3):522-8. PubMed ID: 15351848
[TBL] [Abstract][Full Text] [Related]
18. A new method measuring the interaction between von Willebrand factor and coagulation factor VIII.
Karlman M; Holmström M; Wiman B
Thromb Res; 2011 Jan; 127(1):47-50. PubMed ID: 21094987
[TBL] [Abstract][Full Text] [Related]
19. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
Scandella D
Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
[TBL] [Abstract][Full Text] [Related]
20. A human FVIII inhibitor modulates FVIII surface electrostatics at a VWF-binding site distant from its epitope.
Dimitrov JD; Roumenina LT; Plantier JL; Andre S; Saboulard D; Meslier Y; Planchais C; Jacquemin M; Saint-Remy JM; Atanasov BP; Kaveri SV; Lacroix-Desmazes S
J Thromb Haemost; 2010 Jul; 8(7):1524-31. PubMed ID: 20374449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]